In recent years, the regulatory role of the gut microbiota in the initiation and progression of colorectal cancer (CRC) has attracted growing attention. Among the key microbial contributors, Fusobacterium nucleatum (Fn) has been identified as a critical pathogenic factor in CRC. As an oral anaerobic commensal, Fn is rarely found in the lower gastrointestinal tract of healthy individuals. However, under pathological conditions, it can ectopically colonize the gastrointestinal tract. Once enriched in the colorectal environment, mounting evidence suggests that Fn is involved in multiple aspects of CRC pathogenesis, including initiation, progression, metastasis, and resistance to conventional therapies such as chemotherapy, radiotherapy, and immunotherapy. A recent review by Wei Wei and Diwei Zheng's team at the Institute of Process Engineering systematically outlines the pathogenic mechanisms of Fn in CRC and summarizes both current and emerging strategies for its therapeutic targeting. Furthermore, the authors propose potential approaches to overcome existing challenges in Fn modulation, aiming to facilitate more effective therapeutic interventions and improve clinical outcomes.

Football’s governing body FIFA should drop Coca-Cola as sponsors of the 2025 Club World Cup which begins this week, urge doctors in The BMJ today.